Argos Therapeutics Announces Pricing of $50 Million Public

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Argos Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock and Warrants

DURHAM, N.C., July 28, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq: ARGS ) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis ® technology platform, today announced the pricing of its public offering of 9,090,909 shares of its common stock and accompanying warrants to purchase up to an aggregate of 6,818,181 shares of its common stock at a price of $5.50 per share and accompanying warrant.  Argos expects the gross proceeds of the public offering to be $50 million, before deducting underwriter discounts and expenses payable by Argos.  All of the shares of common stock and accompanying warrants to be sold in the offering are to be sold by Argos. 

Stifel and JMP Securities are acting as joint book-running managers, Needham is serving as the lead manager, and FBR and Roth Capital Partners are acting as co-managers for the offering. The offering is expected to close on or about August 2, 2016, subject to customary closing conditions. 

A shelf registration statement relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (the “SEC”) on May 8, 2015, and declared effective by the SEC on May 14, 2015. The offering is being made only by means of the written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement related to the offering has been filed with the SEC and may be obtained for free by visiting EDGAR on the SEC website at www.sec.gov .  A final prospectus supplement related to the offering will be filed with the SEC.  When available, copies of the final prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained by contacting Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104 or by telephone: (415) 364-2720; or JMP Securities LLC, Attention: Prospectus Department, 600 Montgomery Street, 11th Floor, San Francisco, CA 94111 (415-835-8985).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Argos Therapeutics

Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003 , is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC).  In addition, AGS-003 is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC).  Argos is also developing a separate Arcelis® -based product candidate, AGS-004 , for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients.

Forward-Looking Statements

Any statements in this press release about Argos’ future expectations, plans and prospects, including statements about Argos’ public offering, Argos’ financial prospects, anticipated use of proceeds, future operations and sufficiency of funds for future operations, clinical development of Argos’ product candidates, expectations regarding future clinical trials and future expectations and plans and prospects for Argos and other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," “may,” "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all; whether Argos' cash resources will be sufficient to fund its continuing operations for the periods anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Argos' product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of the preliminary prospectus supplement filed with the SEC on July 27, 2016, and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent Argos’ views as of the date hereof. Argos anticipates that subsequent events and developments will cause Argos’ views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Argos’ views as of any date subsequent to the date hereof.

Investor Contact: John Menditto Argos Therapeutics, Inc. 919-908-0687 jmenditto@argostherapeutics.com  Media Contact: Adam Daley Berry & Company Public Relations 212-253-8881 adaley@berrypr.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 124

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 7

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 415

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 324

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 136

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 77

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 42

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 44

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 258

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation into Inspire Medical Systems: What Investors Need to Know

Updated Category News Views 166

Investigation of Inspire Medical Systems and Shareholder Rights Faruqi & Faruqi, LLP, a prominent player in the field of securities law, is taking proactive steps to investigate potential claims regarding Inspire Medical Systems, Inc. This company has garnered attention recently due to its significant developments and ongoing operations. Investors who have experienced...

Continue Reading
Ecopro BM Faces Downgrade Amidst Battery Industry Challenges

Updated Category News Views 71

Market Response to Ecopro BM's Stock Downgrade Recently, Ecopro BM Co Ltd (247540:KS) faced a significant shift in its market perception as Nomura/Instinet downgraded the company's stock rating from Buy to Neutral. This adjustment comes with a newly revised price target focused on KRW240,000, a notable decrease from the previous KRW290,000. The decision is primarily...

Continue Reading
Exploring the Current State of Sea's Options Trading Landscape

Updated Category News Views 163

Exploring the Current State of Sea's Options Trading Landscape Recent market movements surrounding Sea (NYSE: SE) have sparked considerable interest among investors and traders alike. A comprehensive analysis of the options trading history for Sea reveals notable bearish activity. In our investigation, we identified 16 unusual trades that reflect a cautious outlook among...

Continue Reading
Empowering Women in Whiskey: The Rise of Lythgoe Bourbon

Updated Category News Views 94

Celebrating Women in the Whiskey Industry with Lythgoe Bourbon In a male-dominated field, one entrepreneur is making waves by honoring women in whiskey. The story of Lythgoe Bourbon begins with Dina Coker, who recognized a remarkable trend in the bourbon market. Despite the traditional narrative focused on male brands and locations in Kentucky, women are a significant...

Continue Reading
Waste Connections Declares Quarterly Cash Dividend for Investors

Updated Category News Views 110

Waste Connections Announces Regular Quarterly Cash Dividend Waste Connections, Inc. (TSX/NYSE: WCN) is making strides in providing returns for its shareholders by declaring a regular quarterly cash dividend of $0.315 U.S. per common share. This decision was made by the Company's Board of Directors and reflects their commitment to offering consistent shareholder value. The...

Continue Reading